As of today, on an average, it takes around 15 years for a drug to be designed, developed and approved for safe use in patients. Developing a new drug costs an average of nearly $2.6 billion and 1 in 15000 compounds finally qualify as a drug. Hence decades of efforts are spent with less than 0.1% success rate which leaves around 95% diseases without any cure.
 
Thus we founded NeurophaAI, with a vision to help streamline time consuming processes in the life sciences industry so that the treatment pathways for patients can be optimized.
 
Our mission is to build Artificial Intelligence based solutions that range from the initial phase of drug discovery to the regulatory submission process which will assist pharma companies in getting medicines to market faster and thus making a positive impact on the lives of patients. 
 
With the increase in the amount of publications from regulatory agencies there’s an increasing need for cheaper and faster document processing capabilities and hence Natural Language Processing and Machine Learning Algorithms can help solve these by automating repetitive manual processes thus increasing the efficiency of the entire operating process.
 
Through AI’s ability to mimic human intelligence and perform high scale computational tasks at ease, there’s a tremendous potential to improve drug approval time, reduce drug discovery and development costs and get medications to patients faster. It can also help in critical areas like identifying pandemic prediction and treatment of rare diseases. 
 
We are at the juncture of the entire spectrum of varied opportunities in the field and the scope to contribute to a better world by using AI based solutions to improve patient care is our driving force.